Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
To evaluate the safety and effectiveness of cell therapy using precision cells Combined With TACE in Advanced Liver Cancer.

Eligibility:

Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Liver Cancer.
Precision Cell Immunotherapy|Transcatheter Arterial Chemoembolization|Advanced Liver Cancer
PROCEDURE: TACE|BIOLOGICAL: Precision Cells
Overall survival, 2 years|Progress-free survival, 2 years
Quality of life, Questionnaire will be used., 2 years
A total of 40 patients may be enrolled over a period of 1-2 years.